Advertisement

The Local Tumor Microenvironment

  • Theresa L. Whiteside

Keywords

TIL immune evasion immune surveillance tumor escape inflammation cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–72PubMedCrossRefGoogle Scholar
  2. 2.
    Dworak HF (1986) Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–59CrossRefGoogle Scholar
  3. 3.
    Aller MA, Arias JL, Nava MP, Arias J (2004) Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune and endocrine function systems. Exp Biol Med 229:170–81Google Scholar
  4. 4.
    Ribatti D, Vacca A, Dammacco F (2003) New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer 39:1835–41PubMedCrossRefGoogle Scholar
  5. 5.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virehow? Lancet 357 539–45Google Scholar
  6. 6.
    Mareel M, Leroy A (2003) Clinical cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337–76PubMedGoogle Scholar
  7. 7.
    Kornstein MJ, Brooks JS, Elder DE (1983) Immunoperoxidase localization of lymphocyte subsets in the host responses to melanoma and nevi. Cancer Res 43:2749–53PubMedGoogle Scholar
  8. 8.
    Vacarello L, Kanbour A, Kanbour-Shakir A, Whiteside TL (1993) Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential. Int. J Gynecol Path 12:41–50CrossRefGoogle Scholar
  9. 9.
    Von Kleist S, Berling J, Bohle W, Wittekind C (1987) Immunohistochemical analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int J Cancer 40: 18–23CrossRefGoogle Scholar
  10. 10.
    Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524–36PubMedCrossRefGoogle Scholar
  11. 11.
    Whiteside TL (1993) Tumor Infiltrating Lymphocytes in Human Malignancies, Medical Intelligence Unit, RG Landes Co, Austin, TX.Google Scholar
  12. 12.
    Letessier E, Sacchi M, Johnson JT, Herberman RB, Whiteside TL (1990) The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 130:446–58PubMedCrossRefGoogle Scholar
  13. 13.
    Tanaka H, Tanaka J, Kjaergaard J, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207–17PubMedCrossRefGoogle Scholar
  14. 14.
    Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8:3137–45PubMedGoogle Scholar
  15. 15.
    Fridman WH, Tartour E (1998) Macrophage – and lymphocyte produced Th1 and Th2 cytokines in the tumor microenvironment. Res Immunol 149:651–53PubMedCrossRefGoogle Scholar
  16. 16.
    Whiteside TL, Campoli M, Ferrone S (2005) Tumor induced immune suppression and immune escape: mechanisms and possible solutions. In: Analyzing T Cell Responses. Nagorsen D, Manincola F (eds), Springer Publishers, pp. 43–82Google Scholar
  17. 17.
    Shevach EM (2004) Fatal attraction: tumors becon regulatory T cells. Nature Med 10:900–01PubMedCrossRefGoogle Scholar
  18. 18.
    Barnes L (1996) Pathology of the head and neck: general considerations. In: Myers EN, Suen J-Y (eds) Cancer of the head and neck. WB Saunders Co., Philadelphia, PA, pp17–32Google Scholar
  19. 19.
    Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y, Satomi S (2004) Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 91:1711–17PubMedGoogle Scholar
  20. 20.
    Mihm MC, Clemente C, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases–a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43–47PubMedGoogle Scholar
  21. 21.
    Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mamary tumors to malignancy. J Exp Med 193:727–40PubMedCrossRefGoogle Scholar
  22. 22.
    Miescher S, Whiteside TL, Moretta L, Von Fliedner V (1987) Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138:4004–11PubMedGoogle Scholar
  23. 23.
    Weidmann E, Whiteside TL, Giorda R, Herberman RB, Trucco M (1992) The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res 52:5913–20PubMedGoogle Scholar
  24. 24.
    Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL (2005) Immune response to p53 in patients with cancer: enrichment in tetramer+p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 62:670–79Google Scholar
  25. 25.
    Albers AE, Tsukishiro T, Ferris RL, Whiteside TL, DeLeo AB (2006) T-cell receptor variable gene UPbeta-restricted T lymphocytes are sensitive to apoptosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 12:2394–2403PubMedCrossRefGoogle Scholar
  26. 26.
    Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL (1993) Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer 54:383–90PubMedCrossRefGoogle Scholar
  27. 27.
    Whiteside TL (1992) Tumor infiltrating lymphocytes as antitumor effector cells. Biotherapy 5:47–61PubMedCrossRefGoogle Scholar
  28. 28.
    Whitford P, Mallon EA, George WD, Campbell AM (1990) Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer 62:971–75PubMedGoogle Scholar
  29. 29.
    Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M (1994) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275–82PubMedCrossRefGoogle Scholar
  30. 30.
    NaitoY, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–94Google Scholar
  31. 31.
    Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H (2001) Proliferative activity of intratumoral CD8+ T lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 61:5132–36PubMedGoogle Scholar
  32. 32.
    Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC (1999) Reversed CD4/CD8 percentages of tumor-infiltrating lymphocytes correlate with disease progression in human cervical cancer. Cancer 86:1537–43PubMedCrossRefGoogle Scholar
  33. 33.
    Vitolo D, Kanbour A, Johnson JT, Herberman RB, Whiteside TL (1993) In situ hybridization for cytokine gene transcripts in the solid tumor microenvironment. Eur J Cancer 3:371–77CrossRefGoogle Scholar
  34. 34.
    Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–61PubMedGoogle Scholar
  35. 35.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res 61:4766–72PubMedGoogle Scholar
  36. 36.
    Ramsdell F (2003) Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19:165–68PubMedCrossRefGoogle Scholar
  37. 37.
    Shevach EM (2000) Regulatory T cells I Autoimmunity. Annu Rev Immunol 18:423–49PubMedCrossRefGoogle Scholar
  38. 38.
    Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA (1998) Molecular basis of T-cell inactivation by CTLA-4. Science 282:2263–66PubMedCrossRefGoogle Scholar
  39. 39.
    Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM (2004) Engagement of glucocorticoid induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173:5008–20PubMedGoogle Scholar
  40. 40.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med 10:942–49PubMedCrossRefGoogle Scholar
  41. 41.
    Vlad G, Cortesini R, Suciu-Foca N (2005) License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 174:5907–14PubMedGoogle Scholar
  42. 42.
    Rabinowich H, Reichert EE, Kashii Y, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes. J Clin Invest 101:2579–88PubMedGoogle Scholar
  43. 43.
    Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 21:295–306PubMedCrossRefGoogle Scholar
  44. 44.
    Li X, Liu J, Park JK, Hamilton TA, Rayman P, Klein E, Edinger M, Tubbs R, Bukowski R, Finke J (1994) T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 54:5424–29PubMedGoogle Scholar
  45. 45.
    Reichert TE, Day E, Wagner EM, Whiteside TL (1998) Absent of low expression of the UPzeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58:5344–47PubMedGoogle Scholar
  46. 46.
    Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH (1999) Renal cell carcinoma-derived gangliosides suppress NFUPkappaB activation in T cells. J Clin Invest 104:769–76PubMedGoogle Scholar
  47. 47.
    Ling W, Rayman P, Uzzo R, Clark P, Kim HJ, Tubbs R, Novick A, Bukowski R, Hamilton T, Finke J (1998) Impaired activation of NFUPkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IUPkappaBUPalpha. Blood 92:1334–41PubMedGoogle Scholar
  48. 48.
    Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, Finke JH (1999) Alterations in NFUPkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Nat Cancer Inst 91:718–721PubMedCrossRefGoogle Scholar
  49. 49.
    Baeuerle PA, Baltimore D (1996) NF-kappa B: ten years after. Cell 87:13–20PubMedCrossRefGoogle Scholar
  50. 50.
    May MJ, Ghosh S (1998) Signal transduction through NF-UPkappaB. Immunol Today 19:80–88PubMedCrossRefGoogle Scholar
  51. 51.
    Kuss I, Saito T, Johnson JT, Whiteside TL (1999) Clinical significance of decreased UPzeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5:329–34PubMedGoogle Scholar
  52. 52.
    Whiteside TL (2004) Down-regulation of UPzeta chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865–76PubMedGoogle Scholar
  53. 53.
    Al-Sarireh B, Eremin O (2000) Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. JR Coll Surg Edinb 45:1–16Google Scholar
  54. 54.
    Liu YJ (2001) Dendritic cell subsets and lineages and their functions in innate and adoptive immunity. Cell 106:259–62PubMedCrossRefGoogle Scholar
  55. 55.
    Hansson M, Asea A, Ericsson U, Hermodsson S, Hellstrand K (1996) Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 156:42–47PubMedGoogle Scholar
  56. 56.
    Kiessling R, Kono K, Petersson M, Wasserman K (1996) Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Sem Immunopathol 18:227–42CrossRefGoogle Scholar
  57. 57.
    Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, et al (2001) Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NK-kappaB activation. J Immunol 167:2595–2601PubMedGoogle Scholar
  58. 58.
    Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625–29PubMedGoogle Scholar
  59. 59.
    Banchereau J, Briere F, Caux C, Davoust J, et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedCrossRefGoogle Scholar
  60. 60.
    Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245–52PubMedCrossRefGoogle Scholar
  61. 61.
    Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard K, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466–74PubMedCrossRefGoogle Scholar
  62. 62.
    Gabrilovich D (2004) Mechanisms and functional significance of tumor-induced dendritic cell defects. Nature Med 4:941–52Google Scholar
  63. 63.
    Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755–66PubMedGoogle Scholar
  64. 64.
    Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8:2553–2562PubMedGoogle Scholar
  65. 65.
    Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN (1998) Minimal recruitment and activation of dendritic cells in within renal cell carcinoma. Clin Cancer Res 4:585–93PubMedGoogle Scholar
  66. 66.
    Esche C, Shurin GV, Kirkwood JM, Wang GQ, Rabinowich H, Pirtskhalaishvili G, Shurin MR (2001) Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediated resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 7:974s-79sPubMedGoogle Scholar
  67. 67.
    Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483–90PubMedGoogle Scholar
  68. 68.
    Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC, Lotze MT, Shurin MR (1999) Tumor’s other immune targets: dendritic cells. J Leukocyte Biol 66:336–44PubMedGoogle Scholar
  69. 69.
    Shurin MR, Esche C, Lokshin A, Lotze MT (1999) Apoptosis in dendritic cells. In: Dendritic Cells: Biology and Clinical Applications, Lotze MT, Thomson AW (eds), Academic Press, New York, pp.673–92Google Scholar
  70. 70.
    Shurin GV, Shurin MR, Bykovskaja S, Shogan J, Lotze MT, Barksdale EM Jr (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363–69PubMedGoogle Scholar
  71. 71.
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell functions. Clin Cancer Res 5:2963–70PubMedGoogle Scholar
  72. 72.
    Whiteside TL, Stanson J, Shurin MR, Ferrone S (2004) Antigen processing machinery (APM) in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 173:1526–34PubMedGoogle Scholar
  73. 73.
    Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR (2005) Restoration by IL-15 of MHC class I antigen processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol In PressGoogle Scholar
  74. 74.
    Becker Y (1993) Dendritic cell activity against primary tumors: an overview. In Vivo 7: 187–91PubMedGoogle Scholar
  75. 75.
    Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL (2001) The number of intratumoral dendritic cells and UPzeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91:2136–47PubMedCrossRefGoogle Scholar
  76. 76.
    Giannini A, Bianchi S, Messerini L, Gallo O, Gallina E, Asprella Libonati G, Olmi P, Zampi G (1991) Prognostic significance of accessory cells and lymphocytes in nasopharygeal carcinoma. Pathol Res Pract 187:496–502PubMedGoogle Scholar
  77. 77.
    Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT (1998) Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124:641–46PubMedGoogle Scholar
  78. 78.
    Furukawa T, Watanabe S, Kodama T, Sato Y, Shimosato Y, Suemasu K (1985) T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer 56:2651–656PubMedCrossRefGoogle Scholar
  79. 79.
    Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D (1999) Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 84:309–14PubMedCrossRefGoogle Scholar
  80. 80.
    Tsujitani S, Furukawa T, Tamada R, Okamura T, Yasumoto K, Sugimachi K (1987) Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 59:501–05PubMedCrossRefGoogle Scholar
  81. 81.
    Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K (1990) Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66:2012–16PubMedCrossRefGoogle Scholar
  82. 82.
    Murphy GF, Radu A, Kaminer M, Berg D (1993) Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J Invest Dermatol 100:335S-341SPubMedCrossRefGoogle Scholar
  83. 83.
    O’Brien PM, Tsirimonaki E, Coomber DW, Millan DW, Davis JA, Campo MS (2001) Immunoglobin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection. Cancer Immunol Immunother 50:523–32PubMedCrossRefGoogle Scholar
  84. 84.
    Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP (2001) Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 61:7889–99PubMedGoogle Scholar
  85. 85.
    Fisher ER, Kenny JP, Sass R, Dimitrov NV, Siderits RH, Fisher B (1990) Medullary cancer of the breast revisited. Breast Cancer Res Treat 16:215–29PubMedCrossRefGoogle Scholar
  86. 86.
    Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169:1829–1836PubMedGoogle Scholar
  87. 87.
    Hansen MH, Nielsen HV, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic tumor cells. PNAS 98:12659–64PubMedCrossRefGoogle Scholar
  88. 88.
    Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63:3275–80PubMedGoogle Scholar
  89. 89.
    Kotlan B, Simsa P, Foldi J, Fridman WH, Glassy M, McKnight M, Teillaud JL (2003) Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma. Hum Antibodies 12:113–21PubMedGoogle Scholar
  90. 90.
    Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–89PubMedGoogle Scholar
  91. 91.
    Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T (1996) Oxidative stress by tumor-derived macrophagessuppresses the expression of CD3 UPzeta chain of T-cell receptor complex and antigen-specific cell responses. PNAS 93:13119–24PubMedCrossRefGoogle Scholar
  92. 92.
    Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756–60PubMedGoogle Scholar
  93. 93.
    Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S (2004) Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Cancer 91:469–75Google Scholar
  94. 94.
    Balkwill F, Coussens LM (2004) Cancer: An inflammatory link. Nature 431:405–06PubMedCrossRefGoogle Scholar
  95. 95.
    Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13:114–19PubMedCrossRefGoogle Scholar
  96. 96.
    Matzinger P (1998) An innate sense of danger. Semin Immunol 10:399–415PubMedCrossRefGoogle Scholar
  97. 97.
    Janeway CA, Jr (1992) The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13:11–16PubMedCrossRefGoogle Scholar
  98. 98.
    Whiteside TL, Vujanovic NL, Herberman RB (1998) Natural killer cells and tumor therapy. Curr Topics Microbiol Immunol 230:221–44Google Scholar
  99. 99.
    Lanier LL (2003) Natural killer cell receptor signaling. Curr Opin Immunol 15:308–14PubMedCrossRefGoogle Scholar
  100. 100.
    Whiteside TL, Rabinowich H (1998) The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46:175–184PubMedCrossRefGoogle Scholar
  101. 101.
    Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907–14PubMedCrossRefGoogle Scholar
  102. 102.
    Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:21.1–22.26Google Scholar
  103. 103.
    Hanada T, Yoshimura A (2002) Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13:413–21PubMedCrossRefGoogle Scholar
  104. 104.
    Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–96PubMedCrossRefGoogle Scholar
  105. 105.
    Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappa B functions as a tumor promoter in inflammation-associated cancer. Nature 431:461–66PubMedCrossRefGoogle Scholar
  106. 106.
    Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–50PubMedCrossRefGoogle Scholar
  107. 107.
    Malik STA, Griffin DB, Fiers W, Balkwill FR (1989) Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer 44:918–25PubMedCrossRefGoogle Scholar
  108. 108.
    Bamias A, Dimipoulos MA (2003) Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med 14:459–69PubMedCrossRefGoogle Scholar
  109. 109.
    Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Vascular endothelial growth factor produced by human tumors inhibits the functional maturation of dendritic cells. Nature Med 2:1096–1103PubMedCrossRefGoogle Scholar
  110. 110.
    Ellis LM, Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 32A:2451–60PubMedCrossRefGoogle Scholar
  111. 111.
    Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200:465–70PubMedCrossRefGoogle Scholar
  112. 112.
    Borregaard N, Herlin T (1982) Energy metabolism of human neutrophils during phagocytosis. J Clin Invest 70:550–57PubMedCrossRefGoogle Scholar
  113. 113.
    Toi M (2002) Proinflammation in human tumor microenvironment: its status and implication. Med Sci Monit 8:25–26Google Scholar
  114. 114.
    Whiteside TL (2002) Tumor-induced death of immune cells: its mechanisms and consequences. Sem Cancer Biol 12:43–50CrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Theresa L. Whiteside
    • 1
  1. 1.University of Pittsburgh Cancer Institute and Departments of PathologyImmunology and Otolaryngology University of Pittsburgh School of Medicine Hillman Cancer CenterPittsburgh

Personalised recommendations